BioCentury | Mar 11, 2020
Regulation

Intarcia’s path uncertain after second regulatory stumble for diabetes implant

...GLP-1R agonist exenatide, marketed by AstraZeneca plc (LSE:AZN; NYSE:AZN) in other formulations as Byetta and Bydureon...
BioCentury | Oct 8, 2019
Company News

After remedies to NDA, Intarcia’s diabetes implant under FDA review again

...Shanghai:600783). AstraZeneca plc (LSE:AZN; NYSE:AZN) markets twice-daily exenatide as Byetta, and a once-weekly formulation as Bydureon. Paul...
BioCentury | Mar 13, 2019
Politics & Policy

China releases timeline, priority diseases for revised reimbursement list

...in a note that drugs such as CSPC’s cancer drug Duomeisu doxorubicin, 3SBio diabetes drug Bydureon...
BioCentury | Feb 15, 2019
Tools & Techniques

Heartening predictors in diabetes

...label extension of CV benefit for its SGLT2 inhibitor Farxiga dapagliflozin and its GLP-1R agonist Bydureon...
BioCentury | Dec 1, 2017
Clinical News

CHMP recommends label update to AZ's Bydureon

...EMA's CHMP recommended expanding the label of Bydureon exenatide from AstraZeneca plc (LSE:AZN; NYSE:AZN) to include...
...II diabetes in combination with other glucose lowering treatments, including basal insulin, when use of Bydureon...
...metformin and a thiazolidinedione. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Bydureon exenatide Business: Endocrine/Metabolic Chris Lieu Bydureon exenatide AstraZeneca...
BioCentury | Aug 16, 2017
Clinical News

AZ's Bydureon improves motor function in Phase II for PD

...Data published in The Lancet showed that diabetes drug Bydureon exenatide from AstraZeneca plc (LSE:AZN; NYSE:AZN...
...EXENATIDE-PD trial to treat moderate Parkinson’s disease. In the 60-patient trial, once-weekly 2 mg subcutaneous Bydureon...
...a longer-term study with more participants” to evaluate Bydureon's effect on quality of life (QOL). Bydureon...
BioCentury | Jun 21, 2017
Distillery Techniques

Drug delivery

...marketed for Type II diabetes. AstraZeneca plc , 3SBio Inc. and Alkermes plc market Bydureon (Byetta LAR...
...a long-acting release (LAR) formulation of exenatide, for Type II diabetes. Bristol-Myers Squibb Co. has Exenatide once weekly...
BioCentury | Jun 2, 2017
Company News

AZ and Harvard Pilgrim sign two outcomes-based drug pricing contracts

...as Brilique . Harvard Pilgrim also signed a three-year contract for Type II diabetes treatment Bydureon...
...LAR ) formulation of Byetta exenatide, a synthetic exendin-4 . The insurer will pay for Bydureon...
...LSE:AZN; NYSE:AZN), London, U.K. Harvard Pilgrim Health Care Inc. , Boston, Mass. Business: Cardiovascular, Endocrine/Metabolic Alex Himes Brilinta Bydureon Harvard...
BioCentury | May 19, 2017
Company News

3SBio acquires China rights to Lilly's Humulin

...China to commercialize two other diabetes drugs from AstraZeneca plc (LSE:AZN; NYSE:AZN) -- Byetta and Bydureon...
BioCentury | May 19, 2017
Strategy

Contracting 2.0

...Trulicity dulaglutide. Trulicity competes with Novo Nordisk A/S ’s Victoza liraglutide and AstraZeneca plc ’s Bydureon...
Items per page:
1 - 10 of 337